<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39361927</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2411-2097</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Voprosy virusologii</Title><ISOAbbreviation>Vopr Virusol</ISOAbbreviation></Journal><ArticleTitle>[The Molecular and Biological Patterns Underlying Sustained SARS-CoV-2 Circulation in the Human Population].</ArticleTitle><Pagination><StartPage>329</StartPage><EndPage>340</EndPage><MedlinePgn>329-340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36233/0507-4088-242</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">For four years, SARS-CoV-2, the etiological agent of COVID-19, has been circulating among humans. By the end of the second year, an absence of immunologically naive individuals was observed, attributable to extensive immunization efforts and natural viral exposure. This study focuses on delineating the molecular and biological patterns that facilitate the persistence of SARS-CoV-2, thereby informing predictions on the epidemiological trajectory of COVID-19 toward refining pandemic countermeasures. The aim of this study was to describe the molecular biological patterns identified that contribute to the persistence of the virus in the human population.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">For over three years since the beginning of the COVID-19 pandemic, molecular genetic monitoring of SARS-CoV-2 has been conducted, which included the collection of nasopharyngeal swabs from infected individuals, assessment of viral load, and subsequent whole-genome sequencing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We discerned dominant genetic lineages correlated with rising disease incidence. We scrutinized amino acid substitutions across SARS-CoV-2 proteins and quantified viral loads in swab samples from patients with emerging COVID-19 variants. Our findings suggest a model of viral persistence characterized by 1) periodic serotype shifts causing substantial diminutions in serum virus-neutralizing activity (&gt; 10-fold), 2) serotype-specific accrual of point mutations in the receptor-binding domain (RBD) to modestly circumvent neutralizing antibodies and enhance receptor affinity, and 3) a gradually increasing amount of virus being shed in mucosal surfaces within a single serotype.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This model aptly accounts for the dynamics of COVID-19 incidence in Moscow. For a comprehensive understanding of these dynamics, acquiring population-level data on immune tension and antibody neutralization relative to genetic lineage compositions is essential.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kustova</LastName><ForeName>D D</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0002-8382-275X</Identifier><AffiliationInfo><Affiliation>National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Federal State Budgetary Educational Institution of Higher Education Lomonosov Moscow State University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pochtovyi</LastName><ForeName>A A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-1107-9351</Identifier><AffiliationInfo><Affiliation>National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Federal State Budgetary Educational Institution of Higher Education Lomonosov Moscow State University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shpakova</LastName><ForeName>O G</ForeName><Initials>OG</Initials><AffiliationInfo><Affiliation>Moscow Healthcare Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shtinova</LastName><ForeName>I A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Moscow Healthcare Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>N A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-7399-7628</Identifier><AffiliationInfo><Affiliation>National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleimenov</LastName><ForeName>D A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-9422-7238</Identifier><AffiliationInfo><Affiliation>National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komarov</LastName><ForeName>A G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0009-0000-8597-7125</Identifier><AffiliationInfo><Affiliation>Moscow Healthcare Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gushchin</LastName><ForeName>V A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0002-9397-3762</Identifier><AffiliationInfo><Affiliation>National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Federal State Budgetary Educational Institution of Higher Education Lomonosov Moscow State University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University).</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Vopr Virusol</MedlineTA><NlmUniqueID>0417337</NlmUniqueID><ISSNLinking>0507-4088</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>Введение. Вирус SARS-CoV-2, являющийся возбудителем COVID-19, циркулирует в человеческой популяции 4 года. При этом уже к концу 2-го года не осталось иммунологически наивных лиц в результате активной иммунизации населения вакцинами и естественного контакта с вирусом. Понимание закономерностей, способствующих сохранению вируса в человеческой популяции, позволит лучше прогнозировать эпидемический потенциал COVID-19 и своевременно адаптировать средства противодействия продолжающейся пандемии. Целью данной работы являлось описание выявленных молекулярно-биологических закономерностей, способствующих сохранению вируса в человеческой популяции. Материалы и методы. В течение более 3 лет с начала пандемии COVID-19 проводили молекулярно-генетический мониторинг SARS-CoV-2, включавший в себя сбор назофарингеальных мазков от инфицированных, оценку вирусной нагрузки и последующее полногеномное секвенирование. Результаты. Был установлен профиль доминирующих генетических линий на фоне роста заболеваемости и его изменение на протяжении всего периода мониторинга. Дополнительно изучен состав аминокислотных замен в различных белках SARS-CoV-2 и уровень вирусной нагрузки в составе мазков у последовательно сменявшихся вариантов возбудителя COVID-19. Предложена модель сохранения вируса в человеческой популяции, в рамках которой вирус способен: 1) к периодической смене серотипа (падение вируснейтрализующей активности сывороток более чем в 10 раз); 2) к накоплению дополнительных точечных аминокислотных замен в составе RBD в пределах серотипа для частичного ухода от нейтрализующих антител (снижение вируснейтрализующей активности в 2‒3 раза) и повышения сродства к рецептору; 3) к постепенному увеличению количества выделяемого вируса на слизистых оболочках в пределах одного серотипа. Заключение. Предложенная модель в существенной степени объясняет динамику заболеваемости COVID-19 в Москве. Для более полной характеристики наблюдаемой динамики необходимо получение популяционных данных о динамике напряженности иммунитета и нейтрализующей способности антител в отношении актуального состава генетических линий.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic</Keyword><Keyword MajorTopicYN="N">Mutation</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">VOCs</Keyword><Keyword MajorTopicYN="N">Viral load</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>5</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39361927</ArticleId><ArticleId IdType="doi">10.36233/0507-4088-242</ArticleId></ArticleIdList></PubmedData></PubmedArticle>